I know you guys all know this and Summer has prob written a treatise about it somewhere...but this board looks LONELY, lol...
ENSPIRIT is an international, randomized, open-label study that will enroll approximately 1,100 patients with advanced or metastatic NSCLC who have been previously treated with a first-line platinum-based chemotherapy and have documented disease progression. Patients will be randomized to receive custirsen plus docetaxel or docetaxel alone. The primary objective of the study will be overall survival with additional secondary and exploratory analyses of other efficacy outcomes and biomarker relationships. Two formal interim analyses are planned for stopping the trial early based on inadequate evidence of clinical benefit or futility. No interim analyses for claiming efficacy are planned.
Couldn't agree more Howard. Wish I had something to add but I'm just posting to help address the lonely board problem. Now on to waiting for them to announce that SYNERGY has completed enrollment. After which I guess we wait some more.
Yes, the board demonstrates apathy and lack of buzz for the stock. The upside is the stock remains with only a $200M market cap, the company is now well capitalized, plans are all on course and when and if good news gets people to take notice the stock gains can be huge.
Some one posted recently on Medivations FDA approval. I think MDVN offers a interesting road map for OGXI. The MDVN run started in the months before the anouncement of end of patient accural for their PIII trial and resulted in a 20 fold increase in shareholder value over the ensuing 2 years.I do not know where the tipping point is in this stock but I think we are VERY close.